Medical Developments International Limited · ASX:MVP
Medical Developments International — Shareholder Meeting (October 2022)
13 slides from Medical Developments International's shareholder meeting presentation, Oct 27, 2022
Slide 1: Presentation delivered to Annual General Meeting
27 October 2022 The Companies Office Australian Securities Exchange 20 Bridge St SYDNEY NSW 2000 MVP: Presentation delivered to Annual General Meeting on 27 October 2022 Enclosed is the presentation provided to attendees at the Annual General Meeting on 27 October 2022. Authorised for release by the
Slide 2: FY22 Annual General Meeting
ASX:MVP FY22 ANNUAL GENERAL MEETING 27 OCTOBER 2022 1
Slide 3: Important information
Important information This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, a
Slide 4: Gordon Naylor, Company Chair
Gordon Naylor Company Chair 3
Slide 5: Your Board
Your Board Gordon Naylor David Williams Richard Betts Christine Mary Sontrop Leon Hoare Company Chair Independent Non-executive Independent Non-executive Emmanuel- Independent Non-executive Independent Non-executive Director Director Director Director Donnelly Independent Non-executive Director 4
Slide 6: How to ask a question
How to ask a question • To ask a written question select the Q & A icon • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast window. 5
Slide 7: How to vote
How to vote • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote “click here to change your vote” at any time until the poll is closed 6
Slide 8: FY22 in Review
FY22 in Review Good progress in executing our growth strategy Leadership Funding to team pursue growth Direct sales transformed Green light Effective strategy capability and executive given for management Solid revenue secured established in compensation Phase III of COVID-19 growth following Wester
Slide 9: Brent MacGregor, CEO
Brent MacGregor CEO 8
Slide 10: FY22 Financial Highlights
FY22 Financial Highlights Revenue Pain Management Revenue Respiratory Revenue $22.4m $13.7m $8.2m +37% 1 +29% 1 +53% (underlying) (underlying) Reported NPAT Cash at bank EBIT $(12.4)m $20.4m $(15.9)m 1. Prior year excludes Mundipharma contract termination income of $8.9m 9
Slide 11: FY22 Key Achievements
FY22 Key Achievements • European regional platform established and in-market sales team deployed in France, growth in FY22 affirms direct sales strategy • Leadership team transformed - with strong international and industry experience providing a deeper focus on commercial execution • Functional tea
Slide 12: FY23 Priorities
FY23 Priorities 1. Deliver further growth in France 2. Prepare for expansion in Germany, Italy and Spain 3. Drive penetration in Australian emergency departments 4. Continue to grow market share in Respiratory segment 5. Advance Phase III trial preparations in the USA 11
Slide 13: FY23 Trading Update
FY23 Trading Update We remain optimistic about the Company’s ability to deliver solid revenue growth this year, with good progress to date: • Australia - we continue to build out the structures to support our direct sales strategy in hospital emergency departments. We have appointed four key account
Medical Developments International — Shareholder Meeting (October 2022) on 6ix